Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100SA1Y
Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥20.5bn2023-01-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥6.5bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥17.4bn2022-01-01 → 2022-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥6.8bn2023-01-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.3bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥6.4bn2023-01-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.3bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥768m2022-01-01 → 2022-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.2bn2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥554m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥389m2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥4.8bn2023-01-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥790m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income−¥868m2022-01-01 → 2022-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥48.5bnat 2023-09-30Cons.Assets IFRS
Total assets¥33.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥36.5bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥21.9bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥14.1bnat 2022-12-31Cons.Liabilities IFRS
Net assets / equity¥26.6bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥19.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31dCons.Equity IFRS
Equity (owners)¥24.2bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥21.0bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥18.1bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.0bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥4.4bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥393m2022-01-01 → 2022-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.7bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥4.1bn2022-01-01 → 2022-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥5.0bn2023-01-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥646m2022-01-01 → 2022-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥46.612023-01-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.682023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥8.192022-01-01 → 2022-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥46.132023-01-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.332023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.112022-01-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio50.0%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio61.8%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-09-30−¥24m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-09-30−¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2023-01-01 → 2023-09-30¥2.3bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2023-01-01 → 2023-09-30¥24m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2023-01-01 → 2023-09-30¥888m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2023-01-01 → 2023-09-30¥18.3bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2023-01-01 → 2023-09-30¥5.9bn
—segment totalrevenue2023-01-01 → 2023-09-30¥20.6bn
—segment totalrevenue external2023-01-01 → 2023-09-30¥20.5bn
—segment totalrevenue intersegment2023-01-01 → 2023-09-30¥24m
—segment totalsegment profit2023-01-01 → 2023-09-30¥6.8bn
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 682
ItemContextValueUnit
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration-299280000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration4981492000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-646327000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant12722213000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant18142601000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant11049310000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember47514843
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember47514843
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant47514843
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant47514843
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember1400
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember47470800
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember474708
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember15643
Number of shares issued shares voting rightsCurrentQuarterInstant47487843
Number of voting rights issued shares voting rightsCurrentQuarterInstant474708
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member1400
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member－
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member1400
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0000
Number of shares held in own name treasury shares etcCurrentQuarterInstant1400
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant1400
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0000
Number of male directors and other officersFilingDateInstant8
Number of female directors and other officersFilingDateInstant1
Ratio of female directors and other officersFilingDateInstant0.111
Property plant and equipment IFRSPrior1YearInstant3951217000JPY
Property plant and equipment IFRSCurrentQuarterInstant4973336000JPY
Right of use assets IFRSPrior1YearInstant755167000JPY
Right of use assets IFRSCurrentQuarterInstant723570000JPY
Goodwill IFRSPrior1YearInstant6047721000JPY
Goodwill IFRSCurrentQuarterInstant6774046000JPY
Intangible assets IFRSPrior1YearInstant2928800000JPY
Intangible assets IFRSCurrentQuarterInstant3863731000JPY
Investments accounted for using equity method IFRSPrior1YearInstant622476000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant755823000JPY
Deferred tax assets IFRSPrior1YearInstant184171000JPY
Deferred tax assets IFRSCurrentQuarterInstant230528000JPY
Other financial assets nca IFRSPrior1YearInstant2270162000JPY
Other financial assets nca IFRSCurrentQuarterInstant4445657000JPY
Non current assets IFRSPrior1YearInstant16759717000JPY
Non current assets IFRSCurrentQuarterInstant21766695000JPY
Inventories ca IFRSPrior1YearInstant1693412000JPY
Inventories ca IFRSCurrentQuarterInstant1573751000JPY
Trade and other receivables ca IFRSPrior1YearInstant3122463000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant5410007000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass